Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX-471 Monotherapy or in Combination With Pembrolizumab in Advanced Malignancies
NCT03881488Phase 1Terminated
- Sponsor
- Compass Therapeutics, Inc.
- Start
- May 2019
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ctx-471 in solid tumor, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and 3 more (4 arms), sponsored by Compass Therapeutics, Inc. Primary endpoints: Dose Limiting Toxicities at 6 weeks, Treatment-emergent Adverse Events at 60 days and 1 more. Started May 2019; status: terminated.
02
Drugs
ctx-471
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)mesotheliomamelanoma
Beyond the preview
Go deeper on NCT03881488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03881488.